Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A bright future for KRAS inhibitors

KRAS mutations are among the most prevalent tumor drivers, but targeting them pharmacologically has been challenging. Recent landmark studies have demonstrated promising clinical results of KRASG12C inhibition by using small molecules. Bar-Sagi, and Knelson and Sequist provide their distinct perspectives on this recent tour de force in targeting KRASG12C alterations.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: The path to KRAS targeting.

References

  1. 1.

    Ostrem, J. M. & Shokat, K. M. Nat Rev. Drug Discov. 15, 771–785 (2016).

    CAS  Article  Google Scholar 

  2. 2.

    Canon, J. et al. Nature 575, 217–223 (2019).

    CAS  Article  Google Scholar 

  3. 3.

    Hallin, J. et al. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-19-1167 (2019).

  4. 4.

    Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013).

    CAS  Article  Google Scholar 

  5. 5.

    Castellano, E. & Downward, J. Genes Cancer 2, 261–274 (2011).

    CAS  Article  Google Scholar 

  6. 6.

    Cullis, J., Das, S. & Bar-Sagi, D. Cold Spring Harb. Perspect. Med. 8, a031849 (2018).

    Article  Google Scholar 

  7. 7.

    Fakih, M., O’Neil, B. & Price, T. J. J. Clin. Oncol. 37 (Suppl.), abstr. 3003 (2019).

  8. 8.

    Govindan, R. et al. Ann. Oncol. 30 (Suppl. 5), mdz244.008 (2019).

  9. 9.

    Hosomi, Y. et al. J. Clin. Oncol. https://doi.org/10.1200/JCO.19.01488 (2019).

    Article  Google Scholar 

  10. 10.

    Matikas, A., Mistriotis, D., Georgoulias, V. & Kotsakis, A. Crit. Rev. Oncol. Hematol. 110, 1–12 (2017).

    Article  Google Scholar 

  11. 11.

    Planchard, D. et al. Lancet Oncol. 18, 1307–1316 (2017).

    CAS  Article  Google Scholar 

  12. 12.

    Sequist, L. V. et al. Cancer Res. 79, abstr. CT033 (2019).

    Google Scholar 

  13. 13.

    Arbour, K. C. et al. Clin. Cancer Res. 24, 334–340 (2018).

    CAS  Article  Google Scholar 

  14. 14.

    Oxnard, G. R. et al. J. Clin. Oncol. 33 (Suppl.), abstr. 2509 (2015).

  15. 15.

    Jänne, P. A. in AACR-NCI-EORTC International Conf. on Molecular Targets and Cancer Therapeutics (2019); https://www.mirati.com/wp-content/uploads/2019/10/AACR-NCI-EORTC-Clinical-Data-Presentation_Janne_October-2019-1-1.pdf

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Dafna Bar-Sagi or Lecia V. Sequist.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bar-Sagi, D., Knelson, E.H. & Sequist, L.V. A bright future for KRAS inhibitors. Nat Cancer 1, 25–27 (2020). https://doi.org/10.1038/s43018-019-0016-8

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing